ClinicalTrials.gg
RecruitingNCT07677059BREADTH-EXTUpdated Oct 7, 2026

A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study

A Phase 2 interventional study of KT-621 in Asthma (Diagnosis), sponsored by Kymera Therapeutics, Inc.. Recruiting at 7 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Kymera Therapeutics, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Oct 7, 2026First sites in Germany, Poland and SerbiaStart date moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
264
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,695 studies in Asthma with a site in United States — 135 open to participants now, 188 under way, 19 of them phase 3. Asthma · United States.

Planned enrollment
423rd of 1,353
264 · median 100
Started
2026
with 53 others
Phase 2
292 of 1,695
22 open now
Primary completion
2028-12
later than 151 of 183 live
Registered
1,677th of 1,695
by date

Among the 1,695 studies in Asthma with a site in United States, this one is the 423rd largest by planned enrollment of the 1,353 interventional ones that give a count, is one of 54 that started in 2026, is one of 292 in phase 2, reaches primary completion later than 151 of the 183 other live ones, and was the 1,677th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

135 of the 1,695 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 135 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,695 studies in Asthma with a site in United States, or all of them as a file.
02

Study summary

This Phase 2b open-label, long-term extension study is designed to evaluate the long-term safety and efficacy of KT-621 in participants with asthma who were previously enrolled in the parent study (KT621-AS-202) of KT-621 for asthma. The main goals of this study are to investigate the long-term safety and tolerability of KT-621, the long-term efficacy of KT-621 at treating asthma, and how KT-621 behaves in the body long-term.

03

Conditions studied

  • Asthma (Diagnosis)

Browse trials for

Keywords

  • KT-621
  • STAT6
  • stat6 degrader
  • targeted protein degrader
  • Phase 2
  • phase 2b
  • OLE
  • LTE
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have completed all visits of the parent study, per its protocol, up to the end of treatment (EoT) visit.
  • Must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, other study-related procedures, and questionnaires, including completing the electronic diary (e-diary), for the duration of the study as required by the study protocol.
  • Must agree to requirements in compliance with the clinical study and local requirements.

Exclusion criteria

Exclusion Criteria:

  • Must not have experienced any change in health status during the parent study, which, in the opinion of the Investigator, would interfere with participant safety, study evaluations, or compliance with study procedures; or otherwise make the participant unsuitable for participation in this study.
  • Must not have developed an AE during the parent study, that in the opinion of the Investigator or of the Sponsor's Medical Monitor, could indicate that continued treatment may present an unreasonable risk for the participant.
  • Must not have met permanent discontinuation criteria and/or permanently discontinued study treatment for any reason during the parent study.
  • Must not be a member of the Sponsor or site's team or their immediate family.
  • Must not be unsuitable to enter the study for any other reason, as judged by the Investigator, including potential risk of noncompliance to study procedures.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
264 participants (estimated)

Study arms

  • Experimental
    KT-621

    Drug: KT-621

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: From baseline through Week 52

  2. Incidence of treatment-emergent serious adverse events (SAEs)

    Time frame: From baseline through Week 52

Secondary outcomes

  1. Change from baseline in pre-bronchodilator FEV1

    Time frame: From baseline (as assessed in the parent study) to Week 52

  2. Change from baseline in post-bronchodilator FEV1

    Time frame: From baseline (as assessed in the parent study) to Week 52

  3. Change from baseline in Asthma Control Questionnaire 5-question version (ACQ-5) score

    Time frame: From baseline (as assessed in the parent study) to Week 52

  4. Change from baseline in Standardized Asthma Quality of Life Questionnaire [AQLQ(S)] global Score

    Time frame: From baseline (as assessed in the parent study) to Week 52

  5. Plasma concentration of KT-621 derived from plasma concentration time data

    Time frame: From baseline to Week 52

07

Study locations

7 of 7 sites recruiting
  • Kymera Investigative Site
    Miami, Florida 33173, United States
    Recruiting
  • Kymera Investigative Site
    Tampa, Florida 33607, United States
    Recruiting
  • Kymera Investigative Site
    Dallas, Texas 75209, United States
    Recruiting
  • Kymera Investigative Site
    Berlin, Germany
    Recruiting
  • Kymera Investigative Site
    Poznan, Poland
    Recruiting
  • Kymera Investigative Site
    Kamenitz, Serbia
    Recruiting
  • Kymera Investigative Site
    Užice, Serbia
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2028, 30 months after the start.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's planned 30 months is above that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Jun 2026, on Oct 7, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2026
First posted
Jun 30, 2026
StartActual
Jun 25, 2026was Jul 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added — first sites in Germany, Poland and Serbia
Show 6 added (2 United States, 2 Serbia, 1 Germany, 1 Poland)
  • Kymera Investigative Site · Miami, United States
  • Kymera Investigative Site · Dallas, United States
  • Kymera Investigative Site · Berlin, Germany
  • Kymera Investigative Site · Poznan, Poland
  • Kymera Investigative Site · Kamenitz, Serbia
  • Kymera Investigative Site · Užice, Serbia
Oct 7, 2026
Start date
Jul 2026→Jun 25, 2026 (actual)
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    6 sites added — first sites in Germany, Poland and Serbia
    Show 6 added (2 United States, 2 Serbia, 1 Germany, 1 Poland)
    • Kymera Investigative Site · Miami, United States
    • Kymera Investigative Site · Dallas, United States
    • Kymera Investigative Site · Berlin, Germany
    • Kymera Investigative Site · Poznan, Poland
    • Kymera Investigative Site · Kamenitz, Serbia
    • Kymera Investigative Site · Užice, Serbia
    Start date Jul 2026→Jun 25, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07677059
Lead sponsor
Kymera Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jun 30, 2026
Start date
Jun 25, 2026
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 7, 2026

Study contacts

Kymera Medical Director
Contact
clinicaltrials@kymeratx.com
857-285-5300

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KT-621

Start the discussion